



Table of Contents

Section I: General Information

Chapter 1: The Drug Development Continuum, Preclinical to Market Access	3
Darlène (Dar) Rosario, MBA, BS, RAC-US; Pragnesh Donga, MPharm, MBA, RAC-Drugs; Kathrin Schalper, PhD, RAC-Devices, RAC-US, RAC-CAN, RAC-EU	
Chapter 2: International Harmonization via ICH, WHO, and Other Global Initiatives.....	19
Linda McBride, RPh, RAC-US	

Section II: Nonclinical Studies

Chapter 3: Principles of Good Laboratory Practice and Nonclinical Development.....	27
Neel Kamal Sharma, PhD, MS; Jennifer G. Brown, PhD, RAC-US	
Chapter 4: Safety Pharmacology Studies.....	37
Charlene F. Barroga PhD, DABT; Brian M. Roche, PhD, DSP, DABT; Simon Authier, DVM, PhD, MBA, MSc, DSP	
Chapter 5: Pharmacokinetic and Toxicokinetic Studies.....	53
Tyler Vandivort, PhD, DABT, RAC-Drugs; Dhanraj Deshmukh, PhD, DABT	
Chapter 6: Acute and Chronic Toxicity Assessments	65
Charles Lambert, PhD, DABT, ERT; Brante P. Sampey, PhD, DABT	
Chapter 7: Local Tolerance Studies	77
Ramesh Subramani, DVM, DABT, ERT, DSP, RAC-US	
Chapter 8: Genotoxicity Studies.....	83
Tyler Vandivort, PhD, DABT, RAC-Drugs; Ramesh Subramani, DVM, DABT, ERT, DSP, RAC-US	
Chapter 9: Carcinogenicity Studies	95
Tyler Vandivort, PhD, DABT, RAC-Drugs; Kalaiselvan Ponnusamy, MVSc, DIBTP, DICVP, DABT	
Chapter 10: Developmental and Reproductive Toxicity Assessments.....	107
Charlene F. Barroga, PhD, DABT; Alan M. Hoberman, PhD, DABT, ATSF	
Chapter 11: Regulatory Environmental Risk Assessment of Human Pharmaceuticals.....	121
Margaret L. Fleming, PhD; Sagar Thakali, PhD, IBERA; Jennifer K. Saxe, PhD, MBA	

Section III: Chemistry, Manufacturing, and Controls

Chapter 12: The Global Regulatory Process for the Registration of Active Substances	137
Darlène (Dar) Rosario, MBA, BS, RAC-US; Yuwei Zhang, MD, PhD, MPH, MBA; Robert Falcone, PhD, FTOPRA, FRAPS	

Chapter 13: Biologics and Small Molecules	151
Ben McLaughlin, MSE	
Chapter 14: Coordinating Drug Supply for Clinical and Nonclinical Development	163
Ajay Babu Pazhayattil, DBA, MPharm, CPGP	
Chapter 15: Pharmaceutical Development Studies and Manufacturing Experience	173
Komalkumar Patel, MS; Nikolaos Zacharias, MS; Kingman Ng, PhD; Beat U. Steffen, MSc, MBA, RAC-Devices, FRAPS; Ricki A. Chase, MS; Nicole Beard, PhD, MSc	
Chapter 16: Analytical Method Lifecycle: Management, Practice, and Regulatory Integration.....	201
Nidhi Kotecha, PhD, MPharm, RAC-Drugs; Siegfried Schmitt, PhD	

Section IV: Clinical Trials

Chapter 17: Conducting Clinical Trials: Drug Application Types, Data Requirements, and Obtaining Marketing Approval	217
Sharry Arora, MPharm, MTOPRA, RAC-Drugs	
Chapter 18: Phases of Development (1, 2, 3, 4).....	229
Rowena Cook, MS, RAC-Global, RCC-IVDR; Siegfried Schmitt, PhD	
Chapter 19: Enhancing Diversity in Clinical Trials	257
Monique J. Carter, MS, FRAPS; Zaida Recinos-Vasquez, MS, MS; Leonor Saldanha, PhD, MS; Jennifer Duru, PharmD	
Chapter 20: Health Authority Interactions	275
Jewell D. Martin, MBA, MA, PMP, RAC-US; Marcello Milano, MSc; Angela W. Corona, PhD	
Chapter 21: Pediatrics	297
Karl-Heinz Huemer, MD, PhD; Linda McBride, RPh, RAC-US	
Chapter 22: Region-Specific Studies.....	313
Consuela Stewart	

Section V: Marketing Authorization

Chapter 23: Core Labeling: An Important Global Tool.....	329
Cathleen A. O'Connell, PhD, MS, RPh; Stephanie Turri Lockman, MS	
Chapter 24: Framework for Benefit-Risk Assessment	335
Cristina Damatarca, MD, PGD	
Chapter 25: eCTD and Digital Applications	349
Danini Y. Marin, MSc; Katelyn Jean Mulligan, EMBA, MS	
Chapter 26: Expedited Approval Pathways	359
Yingying Liu, MSc	
Chapter 27: Dossier Requirements.....	401
Jesshanie Tabaniag; Kholoud M. Abdelfattah, MSc, CSRT-HMS; Danini Y. Marin, MSc; Salah Shawky, DrBA; Hannah Jin, BSc; Brix Gil Bayuga, RPh	
Chapter 28: Combination Products	449
Beat U. Steffen, MSc, MBA, RAC-Devices, FRAPS; Ricki A. Chase, MS	

Section VI: Postmarketing Authorization

Chapter 29: Postauthorization Commitments	467
Karin McIntosh, MPharm, RAC-Drugs	
Chapter 30: Transfers and Renewals	477
Pallavi Trivedi, MPH; Rudradutt Singh Vaghela, PhD, RAC-Drugs	
Chapter 31: Product Extensions, Variations, and Supplements	495
Karin McIntosh, MPharm, RAC-Drugs	
Chapter 32: Compliance.....	517
Siegfried Schmitt, PhD; Barbara A. Rusin, MS	
Chapter 33: Recalls.....	531
Siegfried Schmitt, PhD	
Chapter 34: Postmarket Surveillance.....	535
Pallavi Trivedi, MPH; Siegfried Schmitt, PhD; Cansin Gevrek, BS	
Chapter 35: Advertising and Promotion	551
Timothy A. Candy, PharmD, MS, BCPS; Sue Duvall, MPA, RN, BS; Kathleen Grim, MS; Rebecca Lalani, PharmD	
Chapter 36: Market Access: Reimbursement and Pricing.....	567
Pallavi Trivedi, MPH; Rudradutt Singh Vaghela, PhD, RAC-Drugs	
Glossary, Abbreviations, and Acronyms	603
Index	637

Case Studies

Case Study 4-1	46
Case Study 4-2	47
Case Study 5-1	61
Case Study 10-1	117
Case Study 11-1	130
Case Study 19-1	269
Case Study 19-2	271
Case Study 19-3	272
Case Study 22-1	314
Case Study 22-2	314
Case Study 22-3	317
Case Study 22-4	318
Case Study 22-5	319
Case Study 22-6	320
Case Study 26-1	394
Case Study 35-1	562

Figures

Figure 1-1. The Medicinal Product Development Continuum	4
Figure 1-2. Traditional de Novo Product Development Process Versus Product Repurposing	5
Figure 1-3. Phase Transition Duration From Phase 1 Through NDA/BLA Authorization.....	6
Figure 1-4. Phases of Clinical Research	10
Figure 1-5. CTD Triangle	12
Figure 1-6. Communicating Value to Healthcare Stakeholders.....	14
Figure 1-7. Relationship Between Pricing, Reimbursement, and Market Access	14
Figure 2-1. ICH Process of Harmonization.....	21
Figure 4-1. Continuum of Safety Pharmacology Assessments From Acute to Chronic Toxicity Studies	45
Figure 5-1. Drug Exposure Parameters Derived From PK Data	54
Figure 6-1. Phase-Appropriate Nonclinical Development Plan From Acute Studies Through Chronic Toxicity Studies	67
Figure 8-1. Decision Tree for Follow-Up Testing with an Ames-Positive Drug (Active Ingredient).....	91
Figure 9-1. Genotoxic Versus Nongenotoxic Dose-Response Curves	96
Figure 9-2. ICH S1B(R1) Schema for Determining the Added Value of a 2-Year Carcinogenicity Study	103
Figure 10-1. Stages of the Reproduction and Development Cycle (A to F) as Described in ICH S5(R3).....	108
Figure 10-2. Scheme for Fertility and Early Embryonic Development Studies, Embryofetal Development Studies, and Combined Studies	108
Figure 10-3. Scheme for Pre- and Postnatal Development Studies and Enhanced Studies.....	109
Figure 10-4. Scheme for Enhanced Pre- and Postnatal Development Studies in Rabbits for Vaccines2	116
Figure 10-5. Scheme to Determine If Standard Models for Hazard Assessment of Developmental Toxicity Can Be Used for Molecules That Produce Anti-Drug Antibodies	117
Figure 11-1. FDA Categorical Exclusion for Drug Approval – Small Molecules.....	122
Figure 11-2. FDA Studies Required for Drug Approval.....	123
Figure 11-3. EU ERA Process for Drug Approval	125
Figure 11-4. FDA Categorical Exclusion for Drug Approval – Biologics	129
Figure 12-1. Percentage of World Pharmaceutical Market by Economic Bloc.....	138
Figure 12-2. Brazil's API Background Regulations.....	145
Figure 12-3. China's API Registration Procedure.....	147
Figure 12-4. Japan's API Process Review	148
Figure 14-1. Clinical Supply.....	165
Figure 14-2. Routine Challenges in Clinical Supply	167
Figure 14-3. US-Marketed Products API Supply.....	167
Figure 14-4. Example Sample Kit Label and Bottle Label	169
Figure 15-1. Product Requirements	174
Figure 15-2. Factors Impacting Product Requirements – Ishikawa (Fishbone).....	174
Figure 15-3. QbD Elements Flow Chart	175
Figure 15-4. Possible Leachables From a Plastic Bottle.....	185
Figure 15-5. Overview of Different Combination Product Categories	192
Figure 16-1. Analytical Method Lifecycle.....	202
Figure 18-1. Clinical Trial Lifecycle	231
Figure 18-2. Russian Approval Process.....	243
Figure 19-1. Contributing Factors of Clinical Trial Underrepresentation.....	258
Figure 19-2. Demographic Diversity of Global Clinical Trials Participation for New Drugs Approved by the FDA	258
Figure 19-3a. Distribution of Clinical Trial Participants: US Compared to the Rest of World	259
Figure 19-3b. Global Distribution of Clinical Trial Participants by Country Versus US	259
Figure 19-4. Clinical Trial Sex, Race, Age, and Ethnicity Distribution in the US.....	260
Figure 19-5. Percentage of Trials With Participant Levels Above Census	261
Figure 19-6. Representation in Pfizer Trials Versus US Census Level	261
Figure 19-7. OMB Minimum of Race and Ethnicity Categories	263
Figure 19-8. Intrinsic and Extrinsic Ethnic Factors	268
Figure 20-1. CHMP Scientific Advice Process.....	282
Figure 22-1. Requests for Local Clinical Data and Different Therapeutic Areas	314

Figure 22-2. Representative Schematic of Potential Approaches to Conducting Regional-Specific Studies.....	315
Figure 22-3. Clinical Development Strategies Employing Local vs. MRCT Strategies.....	316
Figure 24-1. Continuous Benefit-Risk Assessment for Defining and Maintaining the Safety Profile of Drugs Through the Development Lifecycle	336
Figure 24-2. BRAT Six-Step Process	341
Figure 24-3. EMA Eight-Step PrOACT-URL	342
Figure 24-4. FDA's Benefit-Risk Framework for New Drug Review.....	342
Figure 26-1. Outcome of PRIME Eligibility Requests by Therapeutic Area.....	364
Figure 26-2. Expedited Pathways in Different Development Stages in China	372
Figure 26-3. Standard Marketing Authorization Application Procedures and Expedited Pathways	372
Figure 26-4. General Timeframe of SAKIGAKE	379
Figure 26-5. SAKIGAKE Designation Procedure	379
Figure 26-6. Standard Review, Conditional Early Pathway, Priority Review, and Orphan Drugs in Japan.....	380
Figure 26-7. Conditional Early Pathway Procedures in Japan	380
Figure 27-1. ASEAN CTD	414
Figure 28-1. Overview of Different Combination Product Categories	452
Figure 28-2. Argentinian Regulatory Pathway.....	461
Figure 32-1. How Good Practices Align with the Product Lifecycle.....	518
Figure 32-2. China Drug Regulatory Legislative System.....	525
Figure 32-3. China Drug Regulatory Landscape	526
Figure 33-1. Recall of Clinical Trial Supplies Process Flow	533
Figure 34-1. Possible Decisions During the Signal Evaluation Process.....	539
Figure 34-2. Benefit-Risk Management Cycle of the Medicinal Product	540
Figure 35-1. Example of a Reminder Ad	553
Figure 35-2. Example of a Reminder-Like Ad for a Drug with a Boxed Warning	553
Figure 35-3. General Timeline View of Presubmission Requirements for Subpart E/H Products.....	554
Figure 35-4. Issuance of Enforcement Action Letters Over Time (1997–2024)	559
Figure 36-1. Factors Influencing Medicinal Product Pricing.....	568
Figure 36-2. Process Map for France	570
Figure 36-3. Process Map for Germany	571
Figure 36-4. Mean Length of Time From EMA Authorization to HTA Decision for Oncology Products.....	573
Figure 36-5. Overview of ERP Across Europe (2013).....	574
Figure 36-6. Types of Cost Containment Policies Adopted by Member States	575
Figure 36-7. Process Map for England	578
Figure 36-8. Process Map for Scotland.....	579
Figure 36-9. Timeline of US HTA-Like Bodies	583
Figure 36-10. Overview of the Canada Public System Reimbursement Decision Pathway.....	585
Figure 36-11. Map of Australian Government HTA Processes for Market Entry and Reimbursement Processes.....	590
Figure 36-12. Framework for Pricing Drugs and Devices in Japan.....	592
Figure 36-13. Flow Diagram of HTA in South Korea	593
Figure 36-14. Historical MaHTAS Milestones.....	593

Tables

Table 1 1. Pharmacology Studies – Overview	8
Table 1 2. Toxicology Studies – Overview	8
Table 2-1. Current Members and Observers of the ICH Association	20
Table 3-1. ALCOA+ Principles of Good Documentation Practice.....	30
Table 3-2. Final Study Report Items.....	31
Table 4-1. Cardiac Ion Channels Assessed by In Vitro Assay in Chinese Hamster Ovary (CHO) Cells and Human Embryonic Kidney 293 (HEK293) Cells.....	38

Table 4-2. CV Study Designs and End Points.....	39
Table 4-3. Stand-Alone CV or Combined Cardio-Respiratory Telemetry Studies – Latin Square (4x4) Study Design	40
Table 4-4. Integrated CV or Cardio-Respiratory Telemetry End Points in a Nonrodent, Repeat-Dose, Toxicology Study Design.....	41
Table 4-5. Stand-Alone Rodent Respiratory or CNS (FOB or modified Irwin) Parallel Study Design	42
Table 4-6. Combined Respiratory and CNS (FOB or modified Irwin) Study in Rodent Repeat Dose Toxicology Study Design	42
Table 4-7. Safety Pharmacology Strategies for Pharmaceuticals and Biopharmaceuticals	44
Table 5-1. Parameters for Comparing Drug Exposure Across Studies	55
Table 5-2. Global Implementation of Major ICH Guidance Relevant to Pharmacokinetic and Toxicokinetic Studies	56
Table 5-3. Preclinical Case Study: ZILRETTA.....	61
Table 6-1. International Regulatory and Guidance Documents	66
Table 6-2. Standard List of Clinical Chemistry Parameters Evaluated in GLP Toxicology Studies.....	69
Table 6-3. Standard List of Clinical Chemistry Parameters Evaluated in GLP Toxicology Studies.....	70
Table 6-4. Common Species Used in General Toxicology Studies.....	73
Table 7-1. Maximum Applicable Volume (mL) for Local Tolerance Testing of Parenteral Drugs in Two Commonly Used Animal Models.....	79
Table 7-2. Study Design for Single Dose Subcutaneous Local Tolerance Study in Male New Zealand White Rabbits.....	80
Table 7-3. Testing Procedures for Local Tolerance Testing	81
Table 8-1a. ICH S2(R1) Recommendations for In Vitro Genotoxicity Testing.....	85
Table 8-1b. ICH S2(R1) Recommendations for In Vitro Genotoxicity Testing.....	86
Table 8-2a. ICH S2(R1) Recommendations for In Vivo Genotoxicity Testing.....	87
Table 8-2b. ICH S2(R1) Recommendations for In Vivo Genotoxicity Testing.....	87
Table 8-3. Overview of Common In Vitro and In Vivo Genotoxicity Testing Assays	89
Table 9-1. Global Implementation of Major ICH Guidance on Carcinogenicity	97
Table 9-2. Key Weight of Evidence Factors for Integrated Assessments of Carcinogenic Potential.....	104
Table 10-1. DART Strategy for Pharmaceuticals and Biologics Depending on Relevant Species	111
Table 10-2. Embryofetal Development Study Design Parameters for Rodent, Rabbit and Nonhuman Primate Species	111
Table 10-3. Considerations for the Design of an Enhanced Pre- and Postnatal Development Toxicity Study in Nonhuman Primates.....	113
Table 10-4. Considerations for Design of a Pre- and Postnatal Development Toxicity Study in Rats.....	114
Table 10-5. Potential Species for DART Studies	115
Table 11-1. Studies Required During the EU Environmental Risk Assessment Process	126
Table 12-1. Global Regulatory Active Substances Filing Requirements.....	139
Table 12-2. Master File Classifications.....	142
Table 12-3. Type of Fee (Active Substance Manufacturers).....	144
Table 12-4. Type of Fee (Active Substance Importers and Distributors)	144
Table 13-1. Differences and Similarities in Manufacturing Information Provided in Commercial Product Applications.....	156
Table 13-2. Elucidation of Structure Requirements Based on ICH Guidelines: Q6A and Q6B	157
Table 13-3. Impurities Requirements Based on ICH Q3A, Q3C, Q5C, Q6A, and Q6B and Applicable National Health Authority Guidance.....	157
Table 13-4. Representative Analytical Methods and Rationale Recommended by ICH Q6A and Q6B and ATMP Guidance.....	158
Table 14-1. Components of Clinical Supply Chain Strategy.....	164
Table 14-2. Clinical Development Stages	164
Table 14-3. Comparing Clinical and Commercial Supply.....	166
Table 15-1. Comparison of Regulatory Guidance Based on Quality by Design Principles in Major Markets.....	176
Table 15-2. Summary and Comparison of Artificial Intelligence Guidance in Global Markets Related to Pharmaceutical Development	180
Table 15-3. Container Content/Volume Label Claim/Extractable Volume Test Regional Comparison.....	181
Table 15-4. Dosage Form Compatibility Cases	184
Table 15-5. Typical Packaging Suitability Considerations for Common Classes of Drug Products.....	184
Table 15-6. Extent and Design of Interaction Studies	185
Table 15-7. Dissolution Test Methods Most Commonly Used.....	186
Table 15-8. Biopharmaceutics Classification System.....	187
Table 15-9. Considerations for Specific Dosage Forms	187
Table 15-10. Most Common Routes of Administration: Advantages and Disadvantages.....	188

Table 15-11. Comparison of Agency Guidelines on Multidose Presentations	190
Table 15-12. Regulatory Requirements and Guidance for Combination Products in Key Geographical Areas.....	191
Table 17-1. Key Documents Required for Clinical Trial Application Submission: US.....	219
Table 17-2. Changes to EU Legislation for the Conduct of Clinical Trials, 2022 to 2025	219
Table 17-3. Key Documents Required for Initial Clinical Trial Application Submission: EU.....	220
Table 17-4. Data Requirements for Clinical Investigation Stage: BRICS, APAC, and MENA Countries	222
Table 17-5. Comparison of Data Requirements for Marketing Application Stage: BRICS, APAC, and MENA Countries	222
Table 18-1. Phase I-IV Clinical/Regulatory Terminology	230
Table 18-2. APAC Countries and Respective Regulatory Authorities	245
Table 18-3. Middle East/North Africa Countries and Respective Regulatory Authorities	249
Table 18-4. Countries of Africa and Their Respective Regulatory Authorities	251
Table 19-1. US Clinical Trial Participant Cross-Section Distribution by Sex, Race, and Age for Select Therapeutic Areas	260
Table 19-2. Percentage of Pfizer Studies with Patient Participation at or Above US Census Levels Across Therapy Areas	262
Table 19-3. FDA Diversity Action Plan Elements	266
Table 19-4. Government of Canada Historical GBA Plus Initiatives and Activity Timeline.....	267
Table 20-1. Formal Meetings Negotiated Under PDUFA (Timelines)	277
Table 20-2. Formal Meetings Negotiated Under BsUFA (Timelines).....	278
Table 20-3. CDA-AMC Scientific Advice Process	281
Table 20-4. CDA-AMC Scientific Advice at a Glance.....	281
Table 20-5. Key Timelines for CDA-AMC Scientific Advice Offerings.....	282
Table 20-6. Types of Questions for EMA Scientific Advice	283
Table 20-7. Parallel Scientific Advice Timelines.....	284
Table 20-8. EU/EEA National Competent Authorities and Scientific Advice.....	285
Table 20-9. Simultaneous NCA Participating Countries, Second Phase Pilot.....	290
Table 20-10. PMDA Categories and Content of Consultations for New Medicinal Products	293
Table 21-1. Comparison of Pediatric Development Regulations.....	310
Table 22-1. Time to Regulatory Authority and Ethics Board Approvals in an MRCT	320
Table 22-2. Clinical Trial Applications in North America (Canada, US)	321
Table 22-3. Clinical Trial Applications in Europe (EU, Switzerland, UK).....	321
Table 22-4. Clinical Trial Applications in BRICS Countries.....	322
Table 22-5. Clinical Trial Applications in LATAM Countries.....	322
Table 22-6. Clinical Trial Applications in Asia	323
Table 22-7. Clinical Trial Applications in Oceania	323
Table 22-8. Clinical Trial Applications in Select MENA Countries.....	324
Table 23-1. Distinctions Between Core Labeling and Regional and Local Data Sheets	330
Table 23-2. Sample Structure of a CCDS Based on EU SmPC Headings	331
Table 23-3. Possible Reasons for Discrepancies Between Local Labeling and Core Labeling	333
Table 24-1. A Brief History of the Evolving BRA Initiatives, Methods, and Procedures	338
Table 24-2. UMBRA Steps and Process.....	343
Table 25-1. Advantages and Disadvantages of Electronic Versus Paper-Based CTD Applications.....	350
Table 25-2. Error Severity.....	355
Table 25-3. eCTD 4.0 Implementation Schedule as per ICH Guideline.....	356
Table 26-1. Overview of Expedited Approval Programs in the US	361
Table 26-2. Overview of Expedited Approval Pathways in Argentina.....	362
Table 26-3. Overview of Expedited Approval Pathways in Canada.....	362
Table 26-4. Overview of Expedited Approval Pathways in Mexico.....	363
Table 26-5. Comparison of Conditional Marketing Authorization and Marketing Authorization Under Exceptional Circumstances.....	365
Table 26-6. Overview of Accelerated Approval Pathways in the EU, Switzerland, the UK, and Turkey.....	368
Table 26-7. Overview of Expedited Approval Pathways in Brazil	370
Table 26-8. Summary of Expedited Approval Pathways in India	371
Table 26-9. Overview of Expedited Approval Pathways in China.....	373
Table 26-10. Overview of Expedited Approval Pathways in Australia	374

Table 26-11a. Overview of Expedited Approval Pathways in Japan: SAKIGAKE, Conditional Early Pathway and Priority Review	375
Table 26-11b. Overview of Expedited Approval Pathways in Japan: Orphan Drug Review, Recruitment for Unapproved Drugs and Indications, and Emergency Approval.....	377
Table 26-12. Overview of Expedited Approval Pathways in South Korea.....	381
Table 26-13. Overview of Expedited Approval Pathways in New Zealand	382
Table 26-14. Overview of Expedited Approval Pathways in Taiwan.....	385
Table 26-15. Overview of ASEAN Joint Assessment Procedure.....	387
Table 26-16. Overview of Approval Pathways in Brunei	388
Table 26-17. Overview of Expedited Pathways in Cambodia.....	388
Table 26-18. Overview of Expedited Regulatory Pathways in Indonesia.....	389
Table 26-19. Orphan Drug Designation in Malaysia	390
Table 26-20. Expedited Regulatory Pathways in Malaysia	390
Table 26-21. Overview of the Expedited Regulatory Pathways in Philippines	392
Table 26-22. Overview of Expedited Pathways in Singapore	393
Table 26-23. Eligible Criteria for a Drug to be Considered on the List of Rare Drugs in Vietnam.....	395
Table 27-1. Country Requirements.....	402
Table 27-2. Regulatory Authority and Country Legal Framework.....	407
Table 27-3. Content and Format Requirements	412
Table 27-4. Translation Requirements.....	419
Table 27-5. Dossier Requirement for Collaborative and Reliance Procedures.....	424
Table 27-6. Country-Specific Dossier Requirements Related to Selected Described Pathways	425
Table 27-7. Combination Product Definitions	435
Table 27-8. Combination Product Definitions in Additional Regions.....	437
Table 28-1. Examples of the Different Combination Product Categories.....	452
Table 28-2. Summary of Regulation of Combination Products in Several Asian Jurisdictions.....	459
Table 28-3. LATAM Recognition.....	460
Table 29-1. Regulatory Framework for Postauthorization Studies in Major America Regions.....	468
Table 29-2. Regulations and Guidance Documents in China.....	474
Table 31-1. Americas: Comparison of Regulations Across Jurisdictions	496
Table 31-2. NMRAs and Guidelines for Pharmaceuticals in African Countries.....	510
Table 32-1. Regulations and Guidance for GPvP Management and Reporting.....	519
Table 32-2. PRAC Scope of Recommendations	522
Table 32-3. EU Mutual Recognition Agreements	523
Table 34-1. MAH Reporting Requirements.....	537
Table 36-1. Summary of Time From EMA Authorization to HTA Decision and Outcome	572
Table 36-2. Overview of Reference Pricing and Country Baskets in Europe.....	575
Table 36-3. HTA and Associated Organizations in Selected EU Member States and the UK.....	580
Table 36-4. Comparison of HTA in Germany, France, UK, Italy, and Spain.....	581
Table 36-5. Drugs Eligible for CADTH's Drug Review Processes	583
Table 36-6. Summary of CADTH's Elements and Recommendation Categories	584
Table 36-7. Regulatory Authorities of the BRICS Region and Their Product Categories for Controlled Pricing	585
Table 36-8. Types of Drug Categories Followed in Brazil for Price Fixation.....	586
Table 36-9. Types of Regulatory Programs and Reimbursement Methods in Russia.....	587
Table 36-10. Summary of HTA Status in Select Asian Countries	589
Table 36-11. Selected Products for Japan's MHLW 3-Year HTA Pilot Evaluation.....	591
Table 36-12. MaHTAS 1995–2018 Impact Overview	594
Table 36-13. Regulatory Authorities and Pricing Models in South Asia.....	595

SECTION

I

General Information